2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Ricardo Costa, MD, MSc, discusses the patient population included in the phase 3 OlympiA trial in breast cancer.
Ricardo Costa, MD, MSc, medical oncologist, Department of Breast Oncology, Clinical Investigator Track, Moffitt Cancer Center, discusses the patient population included in the phase 3 OlympiA trial (NCT02032823) in breast cancer.
Findings from the randomized OlympiA trial demonstrated a statistically meaningful improvement in disease-free survival with adjuvant olaparib (Lynparza) vs placebo in patients with BRCA1/2-mutant, HER2-negative, early-stage breast cancer. The large, multinational trial enrolled over 800 patients with germline pathogenic or likely pathogenic BRCA1/2 mutations. Patients were randomized 1:1 to treatment with one year of adjuvant olaparib or placebo, Costa says.
Inclusion criteria for OlympiA stated that patients needed have a diagnosis of HER2–negative disease, Costa adds. Moreover, the majority of patients enrolled on the study had triple-negative breast cancer, Costa concludes.